Braun Stacey Associates Inc Supernus Pharmaceuticals, Inc. Transaction History

Braun Stacey Associates Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 25, 2019	SELL	$29.96 - $38.87 $433,191 - $562,021	-14,459 Closed	0 $0
Q1 2019 Apr 25, 2019	SELL	$32.77 - $41.99 $3.04 Million - $3.9 Million	-92,762 Reduced 86.51%	14,459 $507,000
Q4 2018 Jan 28, 2019	SELL	$30.84 - $49.51 $1.05 Million - $1.68 Million	-33,995 Reduced 24.07%	107,221 $3.56 Million
Q3 2018 Oct 29, 2018	SELL	$42.7 - $56.55 $829,148 - $1.1 Million	-19,418 Reduced 12.09%	141,216 $7.11 Million
Q2 2018 Aug 01, 2018	BUY	$44.1 - $59.85 $6.83 Million - $9.27 Million	154,914 Added 2708.29%	160,634 $9.61 Million
Q1 2018 May 01, 2018	SELL	$37.15 - $46.9 $197,452 - $249,273	-5,315 Reduced 48.16%	5,720 $262,000
Q4 2017 Jan 30, 2018	BUY	$36.4 - $42.6 $401,674 - $470,091	11,035	11,035 $440,000

256

59.3M

47.9K

13.1K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.72B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Braun Stacey Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Braun Stacey Associates Inc with notifications on news.